| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5767082 | ORGANON USA ORGANON | Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists |
Jun, 2015
(8 years ago) | |
| US6653286 | ORGANON USA ORGANON | Gonadotropin releasing hormone antagonist |
Jun, 2018
(5 years ago) | |
Ganirelix Acetate is owned by Organon Usa Organon.
Ganirelix Acetate contains Ganirelix Acetate.
Ganirelix Acetate has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Ganirelix Acetate are:
- US5767082
- US6653286
Ganirelix Acetate was authorised for market use on 29 July, 1999.
Ganirelix Acetate is available in injectable;injection dosage forms.
Ganirelix Acetate can be used as inhibition of premature lh surges in women undergoing controlled ovarian hyperstimulation with fsh.
The generics of Ganirelix Acetate are possible to be released after 16 June, 2018.
Drugs and Companies using GANIRELIX ACETATE ingredient
Market Authorisation Date: 29 July, 1999
Treatment: Inhibition of premature lh surges in women undergoing controlled ovarian hyperstimulation with fsh
Dosage: INJECTABLE;INJECTION
GANIRELIX ACETATE family patents
